

Correspondence



INSTRUCTIONS FOR LETTERS TO THE EDITOR

Editorial comment in the form of a Letter to the Editor is invited; however, it should not exceed 800 words, with a maximum of 10 references and no more than 2 figures (submitted as camera ready hard copy per Journal Guidelines) or tables and no subdivision for an Abstract, Methods, or Results. Letters should have no more than 3 authors. Full name(s) and address of the author(s) should accompany the letter as well as the telephone number, fax number, or E-mail address.

Contact. The Managing Editor, The Journal of Rheumatology, 920 Yonge Street, Suite 115, Toronto, Ontario M6J 3G7, CANADA. Tel: 416-967-5155; Fax: 416-967-7556; E-mail: jrheum@jrheum.com Financial associations or other possible conflicts of interest should always be disclosed.

Silicone Gel Breast Implants

To the Editor:

The report of statistically increased risk of fibromyalgia (FM) in women whose silicone gel breast implants had ruptured received media attention despite its obvious serious flaws¹. First, of women who chose to have implants for cosmetic reasons, the majority (only a minority received them after mastectomy) clearly differ in personality traits and characteristics and self-image from other women. Second, the authors of this study did not ascertain which women had commenced legal actions, and it is well known that the trial lawyers had coached the women's answers and their favorite physicians used questionnaires that were "loaded" (e.g., I have the following symptoms as a result of my breast implants...). Third, FM may have started out as a valid catch-all phrase to help in communication among clinicians, but it no longer has any validity except to designate women (and it is predominantly women who qualify) who evince symptom amplification, social maladjustment, hostility, and a propensity to voice their complaints. The symptoms exist without complaints in rural areas and stable communities, so that they reflect what 19th century sociology distinguished as the difference between community (with its peer oversight) and society (with social disorganization and poor integration). To state that FM is more common in women with ruptured breast implants is to say nothing of importance. From initial scares that breast implants led to scleroderma, human adjuvant disease, connective tissue disease, and atypical connective tissue disease to this assertion that the non-disease FM predominates is really the mountain laboring to produce a mouse. It's high time we disposed of the name and "disease" fibromyalgia, thus giving hope to disaffected sufferers who are being subjected to innumerable useless diagnostic tests and treatments, impertuned by advocacy groups, and recruited by trial lawyers who know it is almost impossible to prove that a self-reported symptom that cannot be verified objectively does not exist. So it is with this study, which continues to attempt to justify US Food and Drug Administration restrictions that were not valid in the first place and represented an overreaction to media circuses (e.g., Connie Chung's notorious exposé) and misguided publications.

As a member of *The Journal's* Editorial Board, I am dismayed that an article that goes to great lengths to analyze the findings leaves out the most

important data: how many women consulted or were referred by lawyers and how many were diagnosed by physicians to whom they were referred by lawyers.

GEORGE E. EHRLICH, MD, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

REFERENCE

1. Brown SL, Pennello G, Berg WA, Soo MS, Middleton MS. Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women. *J Rheumatol* 2001;28:996-1003.

To the Editor:

I read with interest the paper by Brown, *et al*¹ concerning silicone gel breast implant rupture and health status, but I question the appropriateness of the co-mingling of different implant rupture status categories. For critical analyses that led to their major findings, the authors presumably combined women who had intracapsular ruptured implants with women who had intact devices, and then they compared this group to those having ruptured implants with extracapsular silicone migration (I call this group extracapsular rupture). The right half of their Table 4 illustrates the comparison. Based on this categorization, the authors' main finding was that "these data suggest an association between extracapsular silicone from ruptured silicone breast implants and FM [fibromyalgia]."

What was the biological, clinical, and epidemiological rationale for combining these 2 groups? I argue it is better to classify implant status into 3 categories: intact, intracapsular rupture, and extracapsular rupture. Using this classification, one can compare the association between implants with extracapsular rupture to intact implants, and similarly, implants with intracapsular rupture to intact implants — these comparisons are biologically and clinically more relevant and, in my opinion, are the first place to start an epidemiologic analysis involving breast implant rupture. While Brown, *et al* did not present health outcome results for these 3 categories, they provided enough data to do this analysis. When I did, the data showed that fibromyalgia (FM) was indeed *not* associated with ruptured implants, neither for intracapsular nor extracapsular rupture.

From the authors' Table 4, I calculated the number of women in 3 rupture status categories: those with intact implants, those with apparently intracapsular rupture, and those with extracapsular rupture (Table 1). Following Brown, *et al*, Table 1 also displays the number of women by the 2 implant status comparisons the authors reported: (1) any ruptured implant (either intracapsular or extracapsular) versus intact implants, and (2) extracapsular rupture versus intracapsular rupture and intact. The odds ratio (OR), while not given in Table 4 by the investigators, between implant status and health outcome is shown for the 3 conditions the authors found as potentially associated with extracapsular silicone: FM, Raynaud's phenomenon, and "other connective tissue disease."

The OR between FM and extracapsular rupture (compared to intact devices) is 1.88 and not statistically significant. The OR between FM and intracapsular rupture (compared to intact devices) is 0.50 and also not statistically significant. The OR for any rupture versus intact devices is 0.87. It is obvious from Table 1 that the largest difference in FM risk is between extracapsular and intracapsular rupture. If a gradient in risk exists, these data seem to suggest a gradient for FM that is: intracapsular rupture < intact < extracapsular rupture. (While not statistically significant, these data surprisingly seem to point towards a FM risk for women with intracapsular rupture that is half that for women with intact implants, suggesting that intracapsular rupture may *protect* women against FM!) Intuitively, if an association exists between implant status and FM, one would hypothesize based on clinical reasoning that the true gradient would be: intact < intracapsular rupture < extracapsular rupture. Brown, *et al's* data plainly depict no consistent association between ruptured implants of any type and FM when compared to intact devices.

The OR for the comparison the authors reported (i.e., extracapsular rup-

To continue
please scroll
to next page

Table 1. Implant status by self-reported physician diagnosis of 3 health outcomes. Values are expressed as the number of women and odds ratios.

Implant Status	FM			Raynaud's			Other CTD*		
	Yes	No	OR (95% CI) [†]	Yes	No	OR (95% CI)	Yes	No	OR (95% CI)
Extracapsular	18	55	1.88 (0.83–4.29)	6	67	1.84 (0.45–7.94)	9	64	3.66 (0.96–16.80)
Intracapsular	13 [‡]	150	0.50 (0.21–1.17)	3	160	0.39 (0.059–2.04)	6	157	0.99 (0.23–4.91)
Intact	16	92	1 [†]	5	103	1	4	104	1
Any rupture	31	205	0.87 (0.44–1.79)	9	227	0.82 (0.24–3.18)	15	221	1.76 (0.54–7.47)
Intact	16	92		5	103		4	104	
Extracapsular	18	55	2.73 (1.32–5.49)	6	67	2.94 (0.81–10.01)	9	64	3.67 (1.26–10.47)
Intracapsular and intact	29	242		8	263		10	261	

FM: fibromyalgia; CTD: connective tissue disease.

* Dermatomyositis, polymyositis, Hashimoto's thyroiditis, mixed connective tissue disease, pulmonary fibrosis, eosinophilic fasciitis, polymyalgia.

[†] Reference group in OR calculations.

[‡] 95% CI for the OR are by exact methods[§].

[§] Derived from Brown, *et al* Table 4: 236 (No. of women with ruptured implants) × 0.131 (proportion of women with ruptured implants who self-reported a physician diagnosis of FM) = 31 women with ruptured implants self-reporting physician diagnosed FM. 73 (No. of women with extracapsular silicone) × 0.247 (proportion of women with extracapsular silicone who self-reported a physician diagnosis of FM) = 18 women with extracapsular silicone who self-reported a physician diagnosis of FM. The number of women with apparently intracapsular rupture self-reporting a physician diagnosis of FM is 31 – 18 = 13. Other table sample sizes are similarly calculated. Values in bold face are statistically significant.

ture versus intact plus intracapsular rupture) is 2.73 and is statistically significant. However, this is an epidemiologically inappropriate comparison (i.e., by the combining of intact implants with intracapsular rupture) given the authors' own data that show substantial differences in the OR for FM across the 3 implant status categories. By combining the intracapsular rupture and intact implant groups, Brown, *et al* decreased the FM frequency from 14.8% (in the intact-only group) to 10.7% (in the combined group). As a consequence, the difference in FM frequency between the extracapsular rupture group (FM frequency = 24.7%) and the intact/intracapsular rupture group widened beyond that which would have been found if only the intact group was used for the comparison. Combining the implant status categories this way caused the OR to increase and produce a perception of FM risk that the data did not support.

For Raynaud's phenomenon, a parallel analysis of Brown, *et al*'s data similarly shows (like FM) no evidence of an association for extracapsular rupture (Table 1). For the "other connective tissue disease" category, I found a borderline statistically significant association (OR = 3.67) for extracapsular ruptured devices compared to intact implants. According to the authors this category comprised 7 different self-reported physician-diagnosed conditions: dermatomyositis, polymyositis, Hashimoto's thyroiditis, mixed connective tissue disease, pulmonary fibrosis, eosinophilic fasciitis, and polymyalgia. Data for 9 women with extracapsular rupture were spread out over these 7 self-reported diseases, resulting in no clear disease pattern. I find it difficult to interpret the findings for this nonspecific category. I agree with the authors: "It is not possible to determine whether any of these disorders predominated. Our category of other CTD is artificial and therefore those results are difficult to interpret."

In summary, for Brown, *et al*'s data, I argue that it is biologically and clinically more relevant and epidemiologically more appropriate to categorize (and analyze) implant status into 3 categories: intact, intracapsular rupture, and extracapsular rupture. When I analyzed Brown, *et al*'s data this way, it became clear that no association was evident between extracapsular rupture (in fact, for ruptured devices in general) and FM. If the authors believe that intact implants and implants with intracapsular rupture can be plausibly collapsed in the analysis, I respectfully ask them to explain their rationale, especially in light of their own data. Based on 2 of the authors'

written comments about the lack of information on breast implant rupture and disease[§], it seems sensible to me they would want to explore and provide information about the association of health conditions across both types of implant ruptures. If the data are analyzed as I maintain is more appropriate, then women with breast implants can be reassured that ruptured devices have not been found to be associated with FM in this study.

STEVEN J. BOWLIN, DO, MPH, PhD, Dow Corning Corporation, Midland, Michigan, USA.

Dr. Bowlin is an employee of Dow Corning Corporation.

REFERENCES

1. Brown SL, Pennello G, Berg WA, Soo MS, Middleton MS. Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women. *J Rheumatol* 2001;28:996-1003.
2. Brown SL, Silverman BG, Berg WA. Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis. *Lancet* 1997;350:1531-7.
3. StatXact 4[®] for Windows: statistical software for exact nonparametric inference. User manual. Cambridge, MA: Cytel Software Corporation; 1998.

Dr. Brown and Pennello reply

To the Editor:

We appreciate the opportunity to further discuss our results¹.

Dr. Ehrlich voices concern that women with silicone gel breast implants differ in personality traits and characteristics from other women. However, because our study only included women with silicone breast implants, that should not be an issue. Second, he believes that trial lawyers may have influenced women's response to our questionnaire. If the women in this study misreported diagnoses of connective tissue disease or symptoms, for any reason, then that would tend to dilute any association of these outcomes with implant rupture because the women did not know their implant status prior to undergoing magnetic resonance examination. His third point is that fibromyalgia (FM) may be a catch-all and that women with this diagnosis are simply more apt than other women to report, presumably minor, com-

plaints. Despite this opinion, others agree on a scheme for diagnosing this syndrome and it is widely, albeit not universally, recognized¹. Others express opinions similar to Dr. Ehrlich's and question the value of a diagnosis that relies on reporting subjective symptoms². This is a debate not unique to our findings. Dr. Ehrlich, presumably, would find fault with any study in which FM was diagnosed.

Dr. Ehrlich suggests that this study is an attempt to justify US Food and Drug Administration (FDA) restrictions on silicone gel breast implants. The FDA's restrictions of breast implants were due to the manufacturer's failure to prove that their device was safe and effective. This is a basic requirement for any implanted medical device. It should also be remembered that connective tissue disease was not the sole concern, but that local complications such as implant rupture and capsular contracture were considered important³. The FDA opinion on this issue was reiterated by the Institute of Medicine in their assessment, *Safety of Silicone Breast Implants*, when they stated that "Reoperations and local and perioperative complications are frequent enough to be a cause for concern..."⁴.

Dr. Bowlin argues for comparing women with extracapsular silicone to women with intact implants only, as opposed to our comparison of women with extracapsular silicone to all other participants. When the analysis is performed his way, the association with FM is not significant.

Our comparison is biologically and clinically relevant because if extracapsular silicone was the sole cause of FM, then ruptures without extracapsular silicone could be combined with intact implants, particularly since there was no association with rupture when compared to all others. When all 3 categories are compared simultaneously (intact, ruptured, and extracapsular), then there are significant differences among these categories (Fisher-Freeman-Halton exact p value = 0.003). Further, Dr. Bowlin's comparison of extracapsular silicone with intact implants has less power to detect a significant difference than our comparison. Dr. Bowlin reports an odds ratio of 1.88. While not statistically significant, it is still highly suggestive of an association between FM and extracapsular silicone.

A genuine shortcoming of this study was that we were unable to compare women with implants to a comparable group of women without implants. This means that we still do not know whether women with implant rupture are more likely than women without implants to report FM or connective tissue disease. Further study will be required to assess this and obviously an improved study design would include a controlled clinical evaluation of all women in the study.

Our findings indicate that there is an association between extracapsular silicone gel and FM. This does not prove a causal association. In particular, we do not know if the diagnosis of FM came before or after the extracapsular rupture of implants. However, it is suggestive and since this is the first study in which implant status was known for all women in the study, followup studies with a clinical component will be important in clarifying this issue.

S. LORI BROWN, PhD, MPH, GENE PENNELLO, PhD, Office of Surveillance and Biometrics, Food and Drug Administration, Rockville, MD, USA.

REFERENCES

1. Brown SL, Pennello G, Berg WA, Soo MS, Middleton MS. Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women. *J Rheumatol* 2001;28:996-1003.
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. *Arthritis Rheum* 1990;33:160-72.
3. Barsky AJ, Borus JF. Functional somatic syndromes. *Ann Intern Med* 1999;130:910-21.
4. Kessler DA. The basis of the FDA's decision on breast implants. *New Engl J Med* 1992;326:1713-15.
5. Bondurant S, Ernster VL, Herdman R. Safety of silicone breast implants. Washington, DC: Institute of Medicine, National Academy of Sciences; 1999.

Fibromyalgia: Can One Distinguish It from Simulation?

To the Editor:

The article by Khostanteen, *et al*¹ would have major implications in "industrial" and insurance policy/litigation, if there were not major methodology flaws. Premise assumptions and experimental design, however, preclude the article's sweeping conclusion¹.

The question of whether fibromyalgia (FM) can be faked is quite pertinent. Can an individual study or be coached as to how to respond during examination? Perhaps that depends upon the examination — and choice of control points.

What is the role of control points? Campbell, *et al*² found that control points were nontender in patients with FM. While Khostanteen, *et al*¹ note that they have published their disagreement, perhaps an issue is specification of the control points. One could question that the control points chosen in their study¹ (forehead, mid-ulna, hypothenar, lateral gastrocnemius) were too physically distant from FM trigger/tender points to be clinically useful. Yes, forehead tenderness might raise questions of secondary gain, and tenderness in the mid-ulna region might raise questions of general body tenderness, low pain threshold or interpreting touch sensations as pain. However, is that really the issue for assessing fakery or exaggeration?

I would suggest that a much better control point is one adjacent to a FM trigger point. Examining the trapezius ridge or rhomboid trigger points and adjacent scapula provides unequivocal evidence³, in my experience. The points are too close for patients to discriminate. As for pain reporting on examining those points, I have not seen a single patient with FM who has tenderness also in the adjacent scapula. Those individuals with tenderness on scapula pressure also have a general body tenderness, something I classify (my own preconceived notion) separately from FM. Thus, I would suggest that control points do matter — if appropriate ones are chosen, ones for which patient's perception do not allow such "2 point discrimination."

The technique of pain assessment may also provide discrimination. It has been my approach to ask at the onset of examination for the patient to identify any pain produced during that examination. Thus, general or inappropriate tenderness can clearly be recognized — and distinguished from FM. Delaying the question to when specific trigger points are examined may miss that important information.

The arbitrary selection of at least 4 trigger points provides a more uniform group of patients with FM. However, presence of trigger points could be interpreted as a patient with FM, who simply doesn't have enough body regions affected to be entered into controlled studies. That, however, does not qualify them as controls. Would it not be more appropriate that controls be individuals without any trigger points. One certainly would not use as controls in a lupus study individuals who fulfill 3 criteria for lupus. Why then should we for FM?

One further critique must be considered. The control group was recruited from "posted notices in the hospital." Relevance to the general population of controls derived from medical facilities is not established.

Subleties are often of great importance in rheumatologic diagnosis³. The term "trigger points" has been used throughout this discussion. Some might distinguish trigger points and tender points, requiring a referred pattern of pain for use of the former term. It would be of great interest to examine patient pain responses, to assess whether the pain is felt at the site of pressure or whether it occurs in anticipated referral patterns. Clarification of specificity for FM of physical examination findings is indeed an important research subject.

Concern must be expressed that those with an agenda will attempt to turn the article by Khostanteen, *et al*¹ into case law. However, the case has not been made. There is still no evidence that FM can be faked — as long as appropriate control points are assessed.

BRUCE M. ROTHSCHILD, MD. Northeastern Ohio Universities College of Medicine, Youngstown, OH 44512, USA.

REFERENCES

1. Khostanteen I, Tunks ER, Goldsmith CH, Ennis J. Fibromyalgia: Can one distinguish it from simulation? An observer-blind controlled study. *J Rheumatol* 2000;27:2671-6.
2. Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM. Clinical characteristics of fibrositis. I. A blinded controlled study of symptoms and tender points. *Arthritis Rheum* 1983;26:817-24.
3. Rothschild BM. *Rheumatology: A primary care approach*. New York: Yorke Medical Press; 1982.

Dr. Khostanteen replies

To the Editor:

Dr. Rothschild in his letter raises some very important issues. Control points need more exact definition and the most appropriate would be those which remain clinically nontender in the region of referred pain. A number of studies had addressed this question; in our study the design was based on previous work¹. Our experience was that control points become progressively more tender in relationship to the tenderness at the tender points comparing healthy controls to patients with fibromyalgia (FM) or myofascial pain.

As per the concern regarding the technique of pain assessment, the point is well taken. The volunteer group was given information regarding technique of examination of tender points and were already examined by the rheumatologist prior to enrollment into the study.

Another concern of Dr. Rothschild was choice of control group. The inclusion criteria were: no history of chronic pain, which would by the ACR criteria² exclude any FM and clinical findings less than 4 points, which was chosen arbitrarily from population studies³.

As per the question of relevance of controls derived from medical facilities, this population provided a convenient sample of healthy individuals. From our study design the volunteers were randomized to the normal group versus the simulators.

We agree that consistency in the use of terminology is important in respect to tender point versus trigger point descriptions. In our study we use the term of tender points.

As stated in the Discussion this study was not to be meant as a test for malingering, but rather tested the sensitivity, specificity, and accuracy of the ACR criteria to distinguish patients with chronic FM from motivated simulators under the conditions of a clinical trial.

Faculty of Health Sciences,
McMaster University,
Hamilton, Ontario, Canada.

Irena Khostanteen, MD, FRCP.


REFERENCES

1. Tunks E, Crook J, Norman G. Tender points in fibromyalgia. *Pain* 1988;34:11-9.
2. Wolfe F, Smythe HA, Yunus MB. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis Rheum* 1990;33:160-72.
3. Wolfe F, Cathey MA. The epidemiology of tender points: a prospective study of 1520 patients. *J Rheumatol* 1985;12:1164-8.


Unusual Synovial Cyst of the Knee Treated with Fibrin Sealant

To the Editor:

We read with great interest the report by Jerome and McKendry¹, describing a case of synovial cyst of the proximal tibiofibular (PTF) joint. As noted by the authors, this condition is uncommon and no consensus exists on the most appropriate management, although surgical excision is recommended. We describe a case of synovial cyst arising from the PTF joint treated successfully by a fibrin sealant injection.



A



B

Figure 1. Axial (a) and sagittal (b) T2 weighted MR images (2700/105) of right knee. A fluid collection with high signal intensity is seen (arrows) connecting with the proximal tibiofibular joint and extending cranio-caudally in the muscle planes. T: tibia. F: fibula.




Figure 2. Axial T2 weighted (2700/105) MR image made 4 weeks after treatment by fibrin sealant injection method. T: tibia. F: fibula.

A 42-year-old man complained of a 2 month history of atraumatic lateral right knee pain that worsened with ambulation. Medical and surgical history was unremarkable. Examination revealed a focal tenderness around the anterolateral aspect of his right knee, without limitation of range of motion. Distal pulses were palpable, the sensation to light touch was intact distally, and motor function of the leg was normal. Right knee radiographs were normal. Axial and sagittal magnetic resonance imaging (MRI) showed a well encapsulated fluid collection with low signal intensity on T1 weighted and homogeneous high signal intensity on T2 weighted images (Figure 1 A, B), arising from the PTF joint and measuring $40 \times 20 \times 20$ mm.

On the basis of fluid consistency and the location of the lesion a diagnosis of synovial cyst of PTF joint was made^{2,3}. To avoid surgery, a non-operative method was tried by injecting a fibrin sealant (Tissucol Kit, Immuno AG, Vienna, Austria) into the cyst with a fluoroscopic guide after needle aspiration of the contents. His pain resolved within a few days after the procedure. Followup MR study one month later (Figure 2) revealed that the cyst had decreased; the patient was asymptomatic and without relapse after 24 months.

Traditional nonoperative treatment of synovial cysts consists of mechanical rupture followed by applying pressure, aspirating the cyst followed by pressure, or aspirating with injection of a chemical irritant. Although this treatment often relieves symptoms, it is only temporarily effective because of cyst reinflation⁴. Fibrin sealant is a biodegradable surgical tissue adhesive used increasingly in many situations⁵ and it would be clinically useful in wall-to-wall adhesion cystic lesions. Recently Shigeno, *et al*⁶ assessed this substance in the management of cystic lesions of the soft tissue in which previous conservative treatment had failed, including a PTF cyst with multiple aspirations. In light of their successful results, in our patient we sought to inject fibrin sealant into the cyst to adhere to the cyst walls, as a more definitive therapy than aspiration alone. Given the com-

plete resolution of one case after one injection, and the simplicity of the technique, we suggest this method before surgery of synovial cysts.

DAMIAN MIFSUT, MD, PhD; MARIA J. LLORENTE, MD;
FRANCISCO SANCHEZ, MD, PhD, Lluís Alcanyis Hospital, Xativa,
Valencia, Spain.

REFERENCES

1. Jerome D, McKendry R. Synovial cyst of the proximal tibiofibular joint. *J Rheumatol* 2000;27:1096-8.
2. Janzen DL, Peterfy CG, Forbes JR, Tirman PF, Genant HK. Cystic lesions around the knee joint: MR imaging findings. *Am J Roentgenol* 1994;163:155-61.
3. Bianchi S, Abdelwahab IF, Kenan S, Zwass A, Ricci G, Palomba G. Intramuscular ganglia arising from the superior tibiofibular joint: CT and MR evaluation. *Skeletal Radiol* 1995;24:253-6.
4. Cherry JH, Ghormley RK. Bursa and ganglion. *Am J Surg New Series* 1941;LII:319-30.
5. Dunn CJ, Goa KL. Fibrin sealant: a review of its use in surgery and endoscopy. *Drugs* 1999;58:863-86.
6. Shigeno Y, Harada I, Katayama S. Treatment of cystic lesions of soft tissue using fibrin sealant. *Clin Orthop* 1995;321:239-44.

Drs. Jerome and McKendry reply

To the Editor:

The letter from Dr. Mifsut, *et al* on the treatment of proximal tibiofibular (PTF) joint cysts also highlights some diagnostic issues. It would appear that the PTF cyst in their patient was not superficial enough to be detected as a subcutaneous mass on physical examination, but rather was diagnosed by magnetic resonance imaging. How often is "knee" pain caused by an unsuspected, symptomatic PTF cyst? Could a PTF cyst of this size be reliably detected using less expensive and more readily available ultrasound imaging? The sustained improvement following intracyst fibrin sealant (Tissucol Kit) is impressive. We hope these authors, or others, will undertake a prospective trial comparing cyst aspiration to aspiration and injection of fibrin sealant to confirm that the excellent result in this patient is the rule rather than the exception.

DANA JEROME, MD; ROBERT J. MCKENDRY, MD, FRCPC, The Ottawa Hospital, Ottawa, Ontario, Canada.

Assessment of Prothrombotic Risk in Patients with Behçet's Disease Should Include Homocysteine Plasma Levels

To the Editor:

We read with great interest the paper by Toydemir, *et al* regarding the possible role of methylenetetrahydrofolate reductase (MTHFR) gene C677T, factor V (FV) gene G1691A (Leiden), and prothrombin gene G20210A polymorphisms in the genesis of thrombosis in patients with Behçet's disease (BD)¹. The authors found no correlation between thrombosis and MTHFR gene C677T mutation in patients with BD, confirming reports that did not show any association between cardiovascular thromboembolic events and MTHFR 677TT genotype². However, it is of interest that while factor V gene G1691A (Leiden) and prothrombin gene G20210A mutations are recognized as independent thrombotic risk factors, MTHFR 677TT genotype should be considered only as an indirect predisposing factor for thrombosis. Indeed, several reports showed that MTHFR 677TT genotype in association with low plasma folate levels is the major determinant for mild or moderate hyperhomocysteinemia, which is a well known risk factor for both arterial and venous thrombosis^{3,4}. Plasma elevations of total-Hcy (tHcy) are typically caused either by genetic defects in the enzymes involved in Hcy metabolism or, more frequently, by nutritional deficiencies

in vitamin cofactors such as folic acid, vitamin B12 and vitamin B6. A screening for thrombophilic conditions in patients with BD should include not only MTHFR genotyping but also homocysteine folate, and vitamin B12 plasma levels to exactly define the prothrombotic risk.

SILVIO DANESE, MD; ALFREDO PAPA, MD; GIOVANNI GASBARRINI, MD; ANTONIO GASBARRINI, MD; Department of Internal Medicine, Catholic University of Rome, Rome, Italy.

REFERENCES

1. Toydemir PB, Elhan AH, Tukun A, et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behçet's disease. *J Rheumatol* 2000;27:2849-54.
2. Brattstrom L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. *Circulation* 1997;96:3805-6.
3. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. *Thromb Haemost* 1999;81:165-76.
4. Welch GN, Loscalzo J. Mechanisms of disease: homocysteine and atherothrombosis. *N Engl J Med* 1998;338:1042-50.
5. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation* 1996;93:7-9.

Drs. Toydemir, et al reply

To the Editor:

Our primary focus was to evaluate the possible role of 3 polymorphic mutations, alone or in combinations, in thrombogenesis in patients with Behçet's disease.

As we clearly pointed out in the Discussion, serum homocysteine levels may be affected by serum levels of folate, vitamins B6 and B12, cystathionine β -synthetase and methionine synthetase, as well as MTHFR C677T mutation, which we examined in this work¹. Our conclusion that MTHFR C677T mutation is not correlated with thrombogenesis does not preclude the association of these other thrombogenic factors, which, we concur, are worthy of study to expand on our findings.

We are pleased to see Danese and colleagues concur with our approach and we encourage others to extend our findings through similar studies.

PINAR BAYRAK TOYDEMİR, MD, PhD; ATILLA HALİL ELHAN, MS; AJLAN TÜKÜN, MD, PhD; REHA TOYDEMİR, MD; AYSEL GÜRLER, MD; ALTAN TÜZÜNER, MD; IŞIK BÖKESÖY, MD, PhD, Ankara University School of Medicine, Ankara, Turkey.

REFERENCE

1. Toydemir PB, Elhan AH, Tukun A, et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behçet's disease. *J Rheumatol* 2000;27:2849-54.

The Journal of Rheumatology, Volume 28, 2001

The editors and the authors of the papers submitted to *The Journal* are grateful for the help of all our reviewers. Here we acknowledge, with special thanks, those who reviewed 3 or more papers in 2000–2001.

Micha Abeles	Bruce Cronstein	David E. Hastings	Alberto Martini
Steven B. Abramson	John J. Cush	Uwe-Fritjof Hausteijn	Alphonse T. Masi
Mahmoud Abu-Shakra	Maurizio Cutolo	Gillian Hawker	Eric L. Matteson
Jonathan D. Adachi	Jane E. Dacre	Donna J. Hawley	Timothy E. McAlindon
Graciela S. Alarcon	Paul Davis	Brian L. Hazleman	Glenn A. McCain
Donato Alarcon-Segovia	Richard O. Day	Antoine Helewa	Gale A. McCarty
Ashok R. Amin	Jean-Michael Dayer	Philip S. Helliwell	Dennis McGonagle
Bernard Amor	Susan D. Denburg	Evelyn V. Hess	Neil J. McHugh
Boel Andersson-Gäre	Jan Dequeker	Kenshi Higami	David McNeely
Andrew P. Andonopoulos	John A. DiBattista	Stephen A. Hill	Phillip J. Mease
Barbara M. Ansell	Paul A. Dieppe	Gary S. Hoffman	Thomas A. Medsger, Jr.
Frank C. Arnett	Paul J. Doherty	Anthony P. Hollander	Herman Mielants
Ronald A. Asherson	Maxime Dougados	Rikard Holmdahl	Kiyoshi Migita
John S. Axford	Alexandros A. Drosos	Joseph B. Houpt	John J. Miller, III
Paul S. Babyn	John P. Edmonds	Oswaldo Hubscher	Nobuyuki Miyasaka
Elizabeth M. Badley	Keith B. Elkon	James I. Hudson	Michael A. Mont
Meyer S. Balter	Paul Emery	Tom W.J. Huizinga	Larry W. Moreland
John Baum	John M. Esdaile	Gene G. Hunder	Sarah L. Morgan
Francois Beaudet	Luis R. Espinoza	David A. Isenberg	John D. Mountz
Jill J.F. Belch	Christopher H. Evans	J. Charles Jennette	Alastair G. Mowat
David A. Bell	Ronald J. Falk	Norman A. Johanson	Michel Neidhart
Mary J. Bell	Adel G. Fam	Bashar M. Kahaleh	Kusuki Nishioka
Robert M. Bennett	Brian M. Feldman	Alice Kahan	James R. O'Dell
William G. Bensen	David T. Felson	Marcel-Francis Kahn	Kiem G. Oen
Thomas M. Best	Oliver M. FitzGerald	Elizabeth W. Karlson	Darrell Ogilvie-Harris
Johannes W.J. Bijlsma	Paul R. Fortin	Arthur F. Kavanaugh	Akihide Ohta
Howard A. Bird	Irving H. Fox	Edward C. Keystone	William E.R. Ollier
Carol M. Black	Robert I. Fox	Wan-Uk Kim	Nancy J. Olsen
Maarten Boers	Marvin J. Fritzler	Hiroshi Kinoshita	Richard S. Panush
Earl R. Bogoch	Howard A. Fuchs	Alice V. Klinkhoff	Yong-Beom Park
Gilles Boire	Daniel E. Furst	Alisa E. Koch	Christine G. Parks
Robert Bourne	Sherine E. Gabriel	Yrjo T. Kontinen	Harold E. Paulus
Suzanne L. Bowyer	Steffen Gay	J. Manfred Koo	Jean-Pierre Pelletier
Kenneth D. Brandt	Jean-Charles Gerster	Joel M. Kremer	Michelle A. Petri
Jurgen Braun	Edward H. Giannini	Yasuo Kuroki	Ross E. Petty
Barry Bresnihan	David N. Glass	Irving Kushner	Stanley R. Pillemer
Constance E. Brinckerhoff	Richard H. Glazier	James V. Lacey, Jr.	Theodore Pincus
John Brockbank	Charles M. Godfrey	Robert G. Lahita	A. Robin Poole
Wendell D. Bronson	Charles H. Goldsmith	Nancy E. Lane	Janet E. Pope
Ian N. Bruce	Rose Goldstein	Ronald M. Laxer	Kenneth P.H. Pritzker
W. Watson Buchanan	Miguel A. Gonzalez-Gay	Mary C.Y. Lee	Cesar Ramos-Remus
Peter G. Bullough	Susan E. Gowans	Thomas J.A. Lehman	Rolf Rau
Carol S. Burckhardt	Rodney Grahame	Marjatta Leirisalo-Repo	Trude E. Reich
Andrei Calin	Kaisa Granfors	E. Carwile LeRoy	W. Jack Reynolds
Juan J. Canoso	John T. Granton	Carol B. Lindsley	Carlos D. Rose
Hilary A. Capell	Niels A. Graudal	Geoffrey O. Littlejohn	Cheryl F. Rosen
Simon Carotte	Robert A. Greenwald	Martin K. Lotz	James T. Rosenbaum
James T. Cassidy	Peter K. Gregersen	Phyllis LuValle	Alan M. Rosenberg
George P. Chrousos	Marie R. Griffin	Charles G. Mackworth-Young	Naomi F. Rothfield
Maria C. Cid	Wolfgang L. Gross	Rajan Madhok	Robert A.S. Roubey
Christine A. Clark	Pierre-Andre Guerne	Andreas Maetzel	Peter J. Roughley
Daniel J. Clauw	Francis Guillemin	Maren L. Mahowald	Joel Rubenstein
Daniel O. Clegg	Loic Guillevin	Angela H. Mailis	Laurence A. Rubin
Philip J. Clements	Nortin M. Hadler	Walter P. Maksymowych	Robert L. Rubin
Edward H. Cole	Ali H. Hajeer	Kaisa Mannerkorpi	Nicolino Ruperto
Ann B. Cranney	John G. Hanly	Melelaos N. Manoussakis	Anthony S. Russell
Leslie J. Crofford	Manfred Harth	Johanne Martel-Pelletier	Kenneth G. Saag
Peter Croft	Sanshiro Hashimoto	Javier Martin	Tsuyoshi Sakane